Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jumpstarting U.S. Device Trials? FDA Makes Effort In New Draft Guidelines

This article was originally published in The Gray Sheet

Executive Summary

New FDA guidances aim to strike a balance by allowing firms to begin trials earlier through adaptive study designs, while ensuring that patients are adequately protected.

Advertisement

Related Content

FDA Abandons Proposal For Interactive, “Pre-Decisional” IDE
FDA Finalizes Guidance On Early-Stage Clinical Trials
FDA Finalizes Guidance On Early-Stage Clinical Trials
CDRH Officials Talk New Guidance, Post-Market Surveillance And 510(k)s At AdvaMed
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
New Metrics For Clinical Trial Oversight Floated By CDRH Entrepreneurs In Residence
Regulatory News In Brief
Shuren: New Clinical Trial Guidelines In The Works
U.S. Could Speed Device Innovation Through Clinical Research Reforms

Topics

Advertisement
UsernamePublicRestriction

Register

MT030725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel